LNK mutation studies in blast-phase myeloproliferative neoplasms, and in chronic-phase disease with TET2, IDH, JAK2 or MPL mutations.
about
Genomic diversity in myeloproliferative neoplasms: focus on myelofibrosisBlast transformation and fibrotic progression in polycythemia vera and essential thrombocythemia: a literature review of incidence and risk factorsPathogenesis of Myeloproliferative Neoplasms: Role and Mechanisms of Chronic InflammationJAK kinase targeting in hematologic malignancies: a sinuous pathway from identification of genetic alterations towards clinical indicationsGenetics of myeloproliferative neoplasmsGenomic profiling of B-progenitor acute lymphoblastic leukemiaMyeloid malignancies: mutations, models and managementCorrelation of mutation profile and response in patients with myelofibrosis treated with ruxolitinib.The secret life of a megakaryocyte: emerging roles in bone marrow homeostasis controlSafety and efficacy of TG101348, a selective JAK2 inhibitor, in myelofibrosis.Comparison of the Mutational Profiles of Primary Myelofibrosis, Polycythemia Vera, and Essential ThrombocytosisIntegrated genomic analysis illustrates the central role of JAK-STAT pathway activation in myeloproliferative neoplasm pathogenesis.Octa-arginine mediated delivery of wild-type Lnk protein inhibits TPO-induced M-MOK megakaryoblastic leukemic cell growth by promoting apoptosis.JAK inhibitor therapy for myelofibrosis: critical assessment of value and limitations.Annual Clinical Updates in Hematological Malignancies: a continuing medical education series: polycythemia vera and essential thrombocythemia: 2011 update on diagnosis, risk-stratification, and management.Current outlook on molecular pathogenesis and treatment of myeloproliferative neoplasms.Identification of submicroscopic genetic changes and precise breakpoint mapping in myelofibrosis using high resolution mate-pair sequencing.Myeloproliferative neoplasms: from JAK2 mutations discovery to JAK2 inhibitor therapies.JAK2 V617F genotype is a strong determinant of blast transformation in primary myelofibrosis.Clonal evolution revealed by whole genome sequencing in a case of primary myelofibrosis transformed to secondary acute myeloid leukemiaIDH mutations in primary myelofibrosis predict leukemic transformation and shortened survival: clinical evidence for leukemogenic collaboration with JAK2V617FThe Polymorphisms in LNK Gene Correlated to the Clinical Type of Myeloproliferative Neoplasms.14-3-3 regulates the LNK/JAK2 pathway in mouse hematopoietic stem and progenitor cellsGenetic alterations activating kinase and cytokine receptor signaling in high-risk acute lymphoblastic leukemia.The Clinical Significance of IDH Mutations in Essential Thrombocythemia and Primary MyelofibrosisMolecular analyses of 15,542 patients with suspected BCR-ABL1-negative myeloproliferative disorders allow to develop a stepwise diagnostic workflow.Comprehensive review of JAK inhibitors in myeloproliferative neoplasms.Splenic extramedullary hematopoietic proliferation in Philadelphia chromosome-negative myeloproliferative neoplasms: heterogeneous morphology and cytological composition.Increased likelihood of post-polycythemia vera myelofibrosis in Ph-negative MPN patients with chromosome 12 abnormalities.SH2B3 (LNK) mutations from myeloproliferative neoplasms patients have mild loss of function against wild type JAK2 and JAK2 V617F.A nonsynonymous LNK polymorphism associated with idiopathic erythrocytosisNormal and malignant megakaryopoiesis.Lnk adaptor suppresses radiation resistance and radiation-induced B-cell malignancies by inhibiting IL-11 signaling.Molecular determinants of pathogenesis and clinical phenotype in myeloproliferative neoplasms.Myeloproliferative neoplasms 5 years after discovery of JAK2V617F: what is the impact of JAK2 inhibitor therapy?JAK2 inhibitors: are they the solution?Environmental, lifestyle, and familial/ethnic factors associated with myeloproliferative neoplasms.Transformation of a chronic myeloproliferative neoplasm to acute myelogenous leukemia: does anything work?BCR-ABL1-negative chronic myeloid neoplasms: an update on management techniques.The Lnk adaptor protein: a key regulator of normal and pathological hematopoiesis.
P2860
Q26770330-8798D77F-53BC-42E6-ABB6-419C6ED8F4E5Q26777265-A311DA36-522A-4633-81AB-09190A7CC550Q26779960-95D346A5-3AA8-4BCC-8F67-0F030FAB23F9Q26782539-45FF9570-B8DC-4865-93BF-367FD0BB9AD7Q26823651-B1CA00B3-14BD-4261-851E-DCCEAAFE169FQ26829976-67F0EA10-CB4D-4378-B70D-39E9B7592097Q27000577-76B54DE3-483D-4F27-8969-898C4157517EQ27853179-CA0F5669-B9A2-4F45-BE1C-C8BB225126D2Q28082685-C4356048-6208-47E7-B556-09280F67E665Q33393587-D7EA1B03-0E26-4AA1-891F-5490531C6F6DQ33595912-C2DF0BCC-E713-406E-9943-8A91E99EB608Q33697252-231F0DDC-0252-4C62-9ACD-5B06560C940CQ33997280-2A8F145F-6CAF-460B-960F-DA3C28BCFBA2Q34150008-06CD0AF8-6483-4CD2-8FD2-E0B6DF6CAB59Q34166859-2D884F84-41AE-484C-BA6E-6FB84AB361A6Q34302770-62ADC8AD-F830-4341-A1A8-93433466F53EQ34348505-CAC2E631-893D-4C3B-9424-4CDC79BAF6C9Q34629928-076844AE-0750-46AF-9C8D-842762E1466BQ34652224-8581926E-4902-45B2-B9B7-C3BA009892B4Q35217865-03F425C9-DDD7-4347-8670-FDD6C4B2DDBAQ35835653-DA5BA502-AB5D-4838-9CBC-E5C28B7A47C4Q35998214-583181D9-A76F-43D8-957A-8832B1759857Q36005362-BC710459-61B9-40B4-9548-78F1F4165599Q36174146-E3981BCA-C6FF-4E38-9BA6-D09D80209EACQ36364763-B5F5023F-8394-48C7-B455-58E2BBFBB13DQ36366973-48E1776B-3A7B-44CD-8241-D79427824A3AQ36776428-3D76F1BD-B971-46B8-A6F3-D76630EF472CQ36784523-241BD21E-06D4-4232-B177-58CACA14BB48Q36842989-595FF4DF-0082-4408-925E-862DBF33BB41Q36901651-04AE0E87-E5AC-471D-8B19-E4BED5C750EDQ36907588-66B10584-24FB-4CBD-BCA1-73976FB2F2C0Q36909019-2A2584A5-1DAF-4088-8110-EB30216F6290Q37409325-F8367E48-A59D-4B9B-B23D-628D9AD3E72BQ37555785-A82B186A-325D-473C-AA25-6E0FF52936F6Q37877727-FCDA2223-A4A3-4CA9-91D0-2DFDA5B2A4A5Q37950581-9FAE6A7B-7BD3-4128-BB98-EF1A693354A0Q37955142-D537D944-760B-4C9F-8160-975B83275119Q37968531-F64E4C76-DC63-44C1-B270-DB0ADC3DD2D1Q38014534-3D31D492-644C-43C2-8CD6-F5499B298D98Q38044625-0E0ED653-EA36-446B-9C07-792722913469
P2860
LNK mutation studies in blast-phase myeloproliferative neoplasms, and in chronic-phase disease with TET2, IDH, JAK2 or MPL mutations.
description
2010 nî lūn-bûn
@nan
2010年の論文
@ja
2010年論文
@yue
2010年論文
@zh-hant
2010年論文
@zh-hk
2010年論文
@zh-mo
2010年論文
@zh-tw
2010年论文
@wuu
2010年论文
@zh
2010年论文
@zh-cn
name
LNK mutation studies in blast- ...... 2, IDH, JAK2 or MPL mutations.
@en
LNK mutation studies in blast- ...... 2, IDH, JAK2 or MPL mutations.
@nl
type
label
LNK mutation studies in blast- ...... 2, IDH, JAK2 or MPL mutations.
@en
LNK mutation studies in blast- ...... 2, IDH, JAK2 or MPL mutations.
@nl
prefLabel
LNK mutation studies in blast- ...... 2, IDH, JAK2 or MPL mutations.
@en
LNK mutation studies in blast- ...... 2, IDH, JAK2 or MPL mutations.
@nl
P2093
P2860
P356
P1433
P1476
LNK mutation studies in blast- ...... 2, IDH, JAK2 or MPL mutations.
@en
P2093
P2860
P2888
P304
P356
10.1038/LEU.2010.163
P577
2010-08-19T00:00:00Z
P5875
P6179
1029334059